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Abstract
 
In T cells, cAMP-dependent protein kinase (PKA) type I colocalizes with the T cell receptor–
CD3 complex (TCR/CD3) and inhibits T cell function via a previously unknown proximal
target. Here we examine the mechanism for this PKA-mediated immunomodulation. cAMP
treatment of Jurkat and normal T cells reduces Lck-mediated tyrosine phosphorylation of the
TCR/CD3 
 
z
 
 chain after T cell activation, and decreases Lck activity. Phosphorylation of resi-
due Y505 in Lck by COOH-terminal Src kinase (Csk), which negatively regulates Lck, is es-
sential for the inhibitory effect of cAMP on 
 
z
 
 chain phosphorylation. PKA phosphorylates Csk
at S364 in vitro and in vivo leading to a two- to fourfold increase in Csk activity that is neces-
sary for cAMP-mediated inhibition of TCR-induced interleukin 2 secretion. Both PKA type
I and Csk are targeted to lipid rafts where proximal T cell activation occurs, and phosphoryla-
tion of raft-associated Lck by Csk is increased in cells treated with forskolin. We propose a
mechanism whereby PKA through activation of Csk intersects signaling by Src kinases and in-
hibits T cell activation.
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Introduction
 
Engagement of the TCR/CD3 complex leads to activation
of the Src family tyrosine kinases Lck and Fyn (1, 2). These
kinases mediate the initial tyrosine phosphorylation of
immunoreceptor tyrosine-based activation motifs in the
 
TCR/CD3 subunits (e.g., 
 
z
 
 chain) and elicit a complex se-
ries of proximal signaling events. This involves recruitment
of the tyrosine kinase Zap-70 to the 
 
z
 
 chain and subsequent
tyrosine phosphorylation of lipid raft–associated adaptor
 
molecules such as the linker for activation of T cells (LAT)
 
1
 
that, via phosphotyrosine binding, further recruit several
downstream, Src homology 2 (SH2) domain–containing
signaling molecules (for a review, see reference 3). The Src
family of tyrosine kinases are negatively regulated by phos-
phorylation of a conserved COOH-terminal tyrosine resi-
due (Y505 in Lck, Y528 in FynT) by the COOH-terminal
Src kinase, Csk (4–6). Although Csk has substantial homol-
ogy to Src kinases, it lacks the COOH-terminal regulatory
tyrosine found in Src kinases (7). Little or no evidence has
been presented to demonstrate any enzymatic regulation of
Csk (8), such as by other signaling pathways. However, a
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 Cbp, Csk binding protein; Csk, COOH-
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LAT, linker for activation of T cell; PAG, phosphoprotein associated with
glycosphingolipid-enriched membrane domains; PKA, protein kinase A
or cAMP-dependent protein kinase; PKI, protein kinase inhibitor; SH2,
Src homology 2. 
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recently identified LAT-homologous, transmembrane adap-
tor protein called Csk-binding protein (Cbp; reference 9) or
phosphoprotein associated with glycosphingolipid-enriched
membrane domains (PAG; reference 10) with the capacity
to bind Csk, may allow spatial regulation of Csk activity to-
ward Src kinases in lipid rafts (8), and binding of Csk to
Y317 in Cbp/PAG may increase the activity of Csk (11).
cAMP, the levels of which are increased, for example, by
prostaglandin E and 
 
b
 
-adrenergic stimuli, negatively regu-
lates mitogenic signaling pathways at multiple levels (12–
14). In normal T cells, cAMP-dependent protein kinase
(PKA) type I colocalizes with the TCR–CD3 complex and
inhibits TCR-induced cell proliferation via a previously
unknown proximal target (15–17). In T cells from HIV-
infected patients and some patients with common variable
immunodeficiency, increased levels of cAMP and hyperac-
tivation of PKA type I contribute to the T cell dysfunction,
and PKA type I selective antagonists can improve immune
function of patient T cells in vitro up to 300% (18–20).
Now, we report a novel inhibitory pathway in T cells
whereby PKA type I, through activation of Csk leading to
inhibition of Lck-mediated 
 
z
 
 chain phosphorylation, shuts
down the proximal T cell activation. Furthermore, we
demonstrate that the whole PKA type I-Csk-Lck inhibi-
tory pathway spatially is assembled in lipid rafts where the
initial T cell activation takes place.
 
Materials and Methods
 
Cell Culture, Stimulation, and Transfection. 
 
The human leuke-
mic T cell line Jurkat (clone E6.1), Jurkat TAg, a derivate of the
Jurkat cell line stably transfected with the SV40 large T antigen
(21), and the Lck-deficient JCaM1 cell line (22) were kept in log-
arithmic growth in RPMI 1640 supplemented with 10% FCS,
sodium pyruvate, nonessential amino acids, and monothioglyc-
erol. Human peripheral blood T cells were purified from normal
donors by negative selection (18). T cells were activated by the
addition of 5–10 
 
m
 
g/ml of anti-CD3
 
e
 
 mAb OKT-3 or by per-
vanadate treatment. For transfections, cells (2 
 
3
 
 10
 
7
 
) in 0.4 ml
Opti-MEM were mixed with 2–80 
 
m
 
g of each DNA construct in
electroporation cuvettes with a 0.4-cm electrode gap (BioRad
Laboratories) and subjected to an electric field of 250 V/cm with
960 
 
m
 
F capacitance. The cells were expanded in complete me-
dium and harvested after 20 h. To obtain only the transfected cell
population for functional assays, cells were cotransfected with a
plasmid encoding the rat NK cell marker NKR-P1A (a gift from
Dr. J.C. Ryan, VA Medical Center, University of California at
San Francisco, San Francisco, CA) and purified by positive selec-
tion using anti–rat NKR-P1 mAb (clone 3.2.3) and anti–mouse
IgG paramagnetic beads which allows release of bead-bound cells
by digestion of a DNA linker that attaches the Ab to the bead
(Cellection; Dynal).
 
Immunoprecipitations. 
 
Immunoprecipitation of Zap-70, Lck,
and Csk was as described previously (23). For immunoprecipita-
tion of hemagglutinin epitope (HA)-tagged Csk, transfected cells
were disrupted in lysis buffer (50 mM Hepes, pH 7.4, 100 mM
NaCl, 5 mM EDTA, 1% Triton X-100, 10 mM sodium pyro-
phosphate, 1 mM Na
 
3
 
VO
 
4
 
, 50 mM NaF, 1 mM PMSF, and 10
 
m
 
g/ml each of leupeptin, antipain, pepstatin A, and chymostatin).
When cells were stimulated with OKT-3, cell lysates were pre-
 
cleared by incubation with protein A/G–Sepharose beads
(Sigma-Aldrich) for 1 h at 4
 
8
 
C, and subjected to immunoprecipi-
tation with anti-HA mAb (Babco) or anti-Csk Ab (Santa Cruz
Biotechnology, Inc.). After overnight incubation at 4
 
8
 
C, protein
A/G–Sepharose was added, and the incubation continued for 1 h.
Immune complexes were washed three times in lysis buffer and
three times in Csk kinase assay buffer (50 mM Hepes, 5 mM
MgCl
 
2
 
, pH 7.4), followed by Csk kinase assays and Western blot
analysis.
 
Immunoblot Analysis.
 
Detection of phosphotyrosine by anti-
PTyr mAb (4G10; Upstate Biotechnology), and immunoblotting
with anti–Zap-70, anti-Lck, anti-HA, anti-Csk, anti-PKA RI
 
a
 
,
anti-PKA RII
 
a
 
, anti-PKA C, and anti-LAT Abs were as before
(18, 23, 24) except that recently developed mAbs directed against
human RI
 
a
 
 and human RII
 
a
 
 (cat. no. P53620; K. Taskén in
collaboration with Transduction Laboratories) and anti-Csk Ab
from Santa Cruz Biotechnology, Inc. (SC-286) were used.
 
Plasmid Constructs. 
 
The gene-encoding human Csk (25) was
subcloned into the expression vector pEF-BOS/HA at NheI-XbaI
sites. Csk-S364A, Csk-S364C, and Csk-S339A/S340A/T341A
mutants were made by PCR or using a site-directed mutagenesis
kit (Quickchange; Stratagene) and verified by sequencing.
 
Expression of Recombinant Enzymes. 
 
Cloning, expression, and
purification of human Csk has been reported previously (25) and
yielded an enzyme with a specific activity in the range of that of
the native purified enzyme. Recombinant purified catalytic sub-
unit of PKA
 
 (
 
C
 
a
 
; reference 26) was a gift from Dr. F. Herberg
 
,
 
Ruhr University, Bochum, Germany.
 
Phosphorylation of Csk. 
 
Csk was incubated with PKA C sub-
unit at 30
 
8
 
C for the indicated time periods in 50 mM Hepes, pH
7.4, 5 mM MgCl
 
2
 
, 3–5 
 
m
 
M [
 
g
 
-
 
32
 
P]ATP (50–320 Ci/mmol). All
reactions were stopped by boiling samples in SDS sample buffer,
followed by SDS-PAGE. Gels were stained with Coomassie bril-
liant blue, dried, and subjected to autoradiography.
 
In Vitro Tyrosine Kinase Assays.
 
The tyrosine kinase activity
of human Csk was measured as incorporation of [
 
32
 
P]phosphate
into the synthetic polyamino acid poly(Glu,Tyr) 4:1 (Sigma-
Aldrich), abbreviated pEY. A standard protocol was followed (25)
with reaction volumes of 50 
 
m
 
l containing Hepes buffer, pH 7.4,
5 mM MgCl
 
2
 
, 200 
 
m
 
M [
 
g
 
-
 
32
 
P]ATP (0.15 Ci/mmol), 200 
 
m
 
g/ml
pEY, and different amounts of purified Csk. Native or heat-inac-
tivated (65
 
8
 
C for 10 min) C subunit and/or protein kinase inhib-
itor peptide (protein kinase inhibitor [PKI] 6-22 amide; Sigma-
Aldrich) was added where indicated. The incubation temperature
was 30
 
8
 
C, and the incubation times were 12–15 min, if not oth-
erwise stated.
 
Phosphoamino Acid Analysis. 
 
Csk was phosphorylated by
PKA for 30 min as indicated above and subjected to SDS-PAGE.
The band corresponding to phosphorylated Csk was cut from the
dried gel and subjected to partial acid hydrolysis in 6 M HCl at
110
 
8
 
C for 2 h. The acid was evaporated under vacuum and the
hydrolyzed sample was dissolved in 30 
 
m
 
l H
 
2
 
O. 10 
 
m
 
l of sample
(
 
z
 
1,000 cpm of 
 
32
 
P) was separated in two dimensions together
with 10 
 
m
 
g each PSer, PThr, and PTyr. Phosphoamino acid stan-
dards were stained with ninhydrin, and 
 
32
 
P-labeled amino acids
were detected by autoradiography.
 
IL-2 Production Assay.
 
Cell-free supernatants were harvested
from Jurkat T cells after 20 h of culture and stored at 
 
2
 
80
 
8
 
C. IL-2
levels were determined by ELISA (R&D Systems).
 
Lipid Raft Purification. 
 
Isolation of lipid rafts or glycolipid-
enriched membrane microdomains was performed as described in
detail elsewhere (27). In brief, cells were homogenized in 1 ml
ice-cold lysis buffer (described above) by 10 pestle strokes in a 
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Dounce homogenizer, loaded at the bottom of a 40–5% sucrose
gradient and centrifuged at 200,000 
 
g
 
 for 20 h. 0.4-ml fractions
were collected from the top.
 
Results
 
cAMP Inhibition of 
 
z
 
 Chain Phosphorylation Is Dependent
on the COOH-terminal Regulatory Tyrosine 505 in Lck.
 
cAMP treatment of Jurkat T cells (Fig. 1 A) and normal pe-
ripheral blood T cells (Fig. 1 B) inhibited and delayed the
tyrosine phosphorylation of TCR-
 
z
 
 chain and Zap-70 after
T cell activation by anti-CD3 (OKT3; compare lanes 2 and
8 in Fig. 1 A and lanes 2 and 6 in Fig. 1 B). 
 
z
 
 chain and
Zap-70 represent good in vivo substrates for Lck, and their
phosphorylation status can be readily assessed in detergent-
solubilized extracts as the 
 
z
 
 chain is only loosely associated
with lipid rafts in activated T cells (28). Examination of Lck
immune precipitates from cAMP-treated Jurkat T cells also
showed a 50% decrease in kinase activity in vitro (Fig. 1
C). However, no direct downregulation of Lck or Fyn ac-
tivity by PKA could be observed in immune precipitates or
on purified Lck (data not shown). In contrast, Csk activity
was increased two- to threefold after cAMP treatment.
Furthermore, cAMP or PGE2 in combination with isobu-
tyl-methylxanthine (IBMX) increased Csk activity similarly
in peripheral T cells (Fig. 1 D). Transfection of JCaM1 cells
that have a truncated and inactive Lck (Fig. 2, lanes 1–4)
with wild-type Lck (lanes 5–8) or Lck-Y505F (lanes 9–12)
reconstituted TCR-mediated signaling as evident from
anti-CD3–induced 
 
z
 
 chain phosphorylation. Whereas cells
with wild-type Lck showed a distinct reduction in anti-
CD3–induced phosphorylation of 
 
z
 
 chain when pretreated
with 8-CPT-cAMP (top panel, compare lane 8 with lane
6), 
 
z
 
 chain phosphorylation was not inhibited by cAMP in
cells with Lck-Y505F (compare lane 12 with lane 10). We
conclude that the regulatory site Y505 of Lck is required
for cAMP-mediated inhibition of 
 
z
 
 chain phosphorylation.
Figure 1. cAMP inhibits TCR/CD3-induced z
chain phosphorylation. (A) The phosphotyrosine
content of Zap-70 and z chain were examined (top
and middle, respectively) in anti–Zap-70 immuno-
precipitates from untreated (lanes 1–6) and 8-CPT-
cAMP–pretreated (300 mM for 30 min; lanes 7–12)
Jurkat cells stimulated with anti-CD3 Ab (OKT-3)
for the indicated time (0–15 min). Anti–Zap-70
immunoblotting verified equal amounts of Zap-70
(bottom). (B) z chain phosphorylation (top) was
examined in peripheral T cell lysates after anti-CD3
Ab stimulation (0–10 min) of untreated (lanes 1–4)
and 8-CPT-cAMP–pretreated (500 mM for 15
min; lanes 5–8) cells. Anti–z chain immunoblotting
verified equal loading (bottom). (C) Tyrosine ki-
nase activities of Lck and Csk were assessed in im-
munoprecipitates of Jurkat T cells either treated
with 8-CPT-cAMP (300 mM) for 20 min (black
bars) or untreated (white bars; means 6 SEM). Im-
munoblotting verified comparable amounts of Lck
and Csk in immunoprecipitates from 8-CPT-
cAMP–treated and untreated cells. (D) Csk activi-
ties in untreated peripheral T cells (white bars) and
cells treated with 8-CPT-cAMP (500 mM for 5
min) or IBMX (200 mg/ml for 15 min) together
with PGE2 (100 mM for 5 min; black bars) were
assessed as in C. In parallel experiments, PGE2
treatment produced cAMP levels that increased
from 1.6 6 0.4 to 20.8 6 7.3 pmol/106 cells. For
the data presented in A and B, one representative of
three experiments is shown.
Figure 2. cAMP-mediated inhibition of TCR/CD3-induced z chain
phosphorylation is dependent on inactivation of Lck by phosphorylation
at Y505. Lck-deficient JCaM1 cells were transfected with empty pEF
vector alone (vector), with wild-type (wt) Lck, or with mutant Lck-
Y505F, where the COOH-terminal Y505-regulatory site is mutated to
resist inactivation by Csk, and incubated (30 min) in the absence or pres-
ence of 8-CPT-cAMP (300 mM) followed by incubation in the absence
or presence of anti-CD3 Ab (5 min). PO3-z chains (top) were fished with
GST-Zap-70-(SH2)2 and detected by phosphotyrosine immunoblotting
(reference 40). All lanes contain the endogenous truncated Lck present in
JCaM1 cells (catalytically inactive; lower bands), whereas full-length Lck
is present in equal amounts in transfected cells (lower panel; lanes 5–12).
One representative of three experiments is shown. 
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This implicates Csk as a target for regulation by PKA, and
we next explored that possibility.
 
PKA Phosphorylation Activates Csk. 
 
Fully active recom-
binant Csk (25) was readily phosphorylated by C
 
a
 
 of PKA
(Fig. 3 A; lane 1, arrow), whereas no phosphorylation of
Csk was detected when incubated with heat-inactivated
(65
 
8
 
C for 10 min) C
 
a
 
 (lane 2). Incubation of recombinant
Csk with the recombinant catalytic subunit of PKA (C
 
a
 
)
more than doubled the Csk-catalyzed phosphorylation of
pEY compared with Csk incubated alone (Fig. 3 B, com-
pare bar 2 with bar 1). This effect was not seen with heat-
inactivated C
 
a (bar 3). Furthermore, the increase in Csk
activity in the presence of native Ca was strongly reduced
by the addition of PKI, a specific inhibitor of PKA (bar 4).
PKA itself did not phosphorylate pEY (data not shown). In
the presence of heat-inactivated Ca, Csk activity was con-
stant for the first 10 min and then declined, whereas the ac-
tivity curve was much steeper in the presence of native Ca
and the activity was approximately twofold higher at each
time point (Fig. 3 C). Increasing concentrations of Ca sub-
unit led to a saturable increase in activation of Csk, reach-
ing a maximum around a twofold molar excess of C sub-
unit over Csk (Fig. 3 D). Incubation of pEY with
increasing concentrations of Csk demonstrated a concen-
tration-dependent increase in phosphate transfer, which
was approximately twofold higher at all concentrations in
the presence of a fixed amount of native C (Fig. 3 E).
To look at a normal substrate for Csk, heat-inactivated
Lck was used as substrate and the activity of Csk in the
presence and absence of PKA was examined. When Csk
was limiting in the reaction, Csk-mediated tyrosine phos-
phorylation of Lck was 4.8-fold stronger in the presence
than in the absence of PKA (Fig. 4).
Phosphorylation of Csk-S364 Is Necessary for the PKA Regu-
lation of Csk in Intact T Cells. Phosphoamino acid analysis
of Csk phosphorylated by PKA demonstrated strong label-
ing on phosphoserine (Fig. 5 A). Tryptic peptide mapping
of Csk phosphorylated by PKA revealed two major radio-
active spots both of which contained PSer (Fig. 5 B, pep-
tides 1 and 2). The human Csk amino acid sequence con-
Figure 3. PKA-mediated phosphorylation in-
creases the tyrosine kinase activity of Csk. (A) Csk
(10 ng/ml) was incubated with native Ca (5 ng/ml
active; lane 1) and heat-inactivated (658C for 10
min) Ca (lane 2) and [g-32P]ATP and subjected to
SDS-PAGE and autoradiography. Native Ca alone
(lane 3), heat-inactivated Ca alone (lane 4), and
Csk incubated alone (lane 5) were included as con-
trols. Arrows indicate phosphorylated Csk (50 kD)
and autophosphorylated Ca (40 kD). (B) Csk (1
ng/ml) kinase activity when incubated alone (1), in
the presence of native (2), or heat-inactivated (658C
for 10 min) (3) Ca (2 ng/ml; means 6 SD, n 5 5).
Coincubation of Csk and PKI (85 mM) with (4) or
without (5) native Ca is also shown. (C) Time-
dependent phosphorylation of pEY by Csk (1 ng/
ml) in the presence of native (s) and heat-inacti-
vated (658C for 10 min) (d) Ca (2 ng/ml). Each
experiment was performed with single point mea-
surements, and one representative of a total of
seven assays is shown. (D) The effects of different
amounts (0–2 ng/ml) of native (s) and heat-inacti-
vated (d) Ca on Csk (1 ng/ml)-catalyzed phos-
phate transfer to pEY. Duplicate measurements
were performed, and one representative assay of a
total of four is shown. (E) Csk (0–2 ng/ml) concen-
tration-dependent phosphotransfer in the presence
of a constant amount of native (2 ng/ml active; s)
or heat-inactivated (d) Ca. All samples were as-
sayed in duplicate and error bars (half range) are
shown. Where error bars are not visible, they are
within the point. One representative experiment of
four is presented.501 Vang et al.
tains one putative phosphorylation site that fits the motif
preferred by PKA, at amino acids 361–364 in the sequence
KKFS. A Csk-S364A mutant was only weakly phosphory-
lated by PKA (Fig. 5 B, and data not shown), and both ma-
jor tryptic peptides (1 and 2) were missing compared with
wild-type Csk phosphorylated by PKA (Fig. 5 B). The ob-
servation that two phosphorylated peptides disappeared by
mutation of a single residue is probably because of partial
proteolysis by trypsin. To assess the phosphorylation of Csk
in intact cells, Jurkat T cells were metabolically labeled
with  32Pi, and anti-Csk immunoprecipitates were analyzed
by tryptic peptide mapping (Fig. 5 C). Whereas Csk from
untreated cells contained a few weakly labeled phospho-
peptides, treatment with cAMP or PGE1 induced the ap-
pearance of one strong (peptide 1) and three weaker spots
(peptides 2–4). Peptides 1 and 2 comigrated with those in
Fig. 5 B, as shown by eluting peptides from the maps with
PGE1-induced in vivo–labeled and recombinant Csk and
rerunning mixtures with equal amounts of radioactivity on
new maps (Fig. 5 D). To determine the site of phosphory-
lation by PKA in intact cells, Jurkat cells transfected with
HA-tagged wild-type and mutant Csk were metabolically
labeled and then stimulated with cAMP (Fig. 5 C, right
two panels). Tryptic peptide mapping revealed that whereas
HA-Csk phosphopeptides (1, 3, and 4) comigrated with
those of endogenous Csk, an S364C mutation abrogated
labeling of peptide 1. The Csk-S364C mutant was catalyti-
cally active both when expressed in Escherichia coli and Jur-
kat TAg cells (Fig. 6, A and C), whereas Csk-S364A was
not. Perhaps Cys, but not Ala, in position 364 permitted a
normal folding of Csk. Another site at the activation loop
of Csk in the sequence KEASST (amino acids 336–341)
could also potentially be phosphorylated by PKA, although
not fully consistent with the motif preferred by PKA. This
last region is often the site of kinase activation by autophos-
phorylation (29) or transphosphorylation by another kinase,
for example, mitogen-activated protein kinase (MAPK) ac-
tivation by MAPK kinase (30). The extent of PKA-medi-
ated phosphorylation of a Csk-S339A/S340A/T341A mu-
tant (Csk-AAA) was comparable to that of wild-type Csk,
and its tryptic peptide map was identical to that of wild-
type (data not shown). A PKA-mediated increase in the ki-
nase activity of this latter mutant and wild-type, but not
Figure 4. PKA phosphoryla-
tion increases the tyrosine kinase
activity of Csk towards an en-
dogenous substrate. Tyrosine
phosphorylation of heat-inacti-
vated (658C for 10 min) purified
Lck enzyme (30 ng/ml, cat. no.
14-106; Upstate Biotechnology)
by Csk (0.3 ng/ml) was assessed
either in the presence or absence
of PKA catalytic subunit Ca (10 ng/ml) in a buffer containing 5 mM
Mg21 and 200 mM ATP at 308C for 10 min. Reactions were stopped by
the addition of SDS sample buffer, subjected to SDS-PAGE, and phos-
photyrosine content of Lck was assessed by antiphosphotyrosine immu-
noblotting (4G10). Densitometric scanning was performed to evaluate the
level of Csk-mediated tyrosine phosphorylation of Lck in the absence and
presence of PKA. n.d., not done.
Figure 5. Mapping of Ser364 in Csk as a
phosphorylation site for PKA in T cells. (A)
Phosphoamino acid analysis of Csk phos-
phorylated by PKA. Csk (3 ng/ml) was in-
cubated with PKA (GST-Cb; 1.5 ng/ml ac-
tive). (B) Wild-type (wt) Csk and mutant
Csk-S364A were phosphorylated by Ca in
vitro and subjected to tryptic peptide map-
ping (reference 41). (C) Tryptic peptide
maps of 32Pi-Csk obtained by metabolic la-
beling of Jurkat T cells (reference 42).
Endogenous Csk was immunoprecipitated
from untreated, 8-CPT-cAMP–treated (300
mM for 30 min), or PGE1/IBMX-treated
(10 mM/200 mg/ml for 5 min) cells. HA-
tagged Csk or Csk-S364C was immunopre-
cipitated with an anti-HA mAb from trans-
fected cells treated with 8-CPT-cAMP (300
mM for 30 min). To allow for production of
enough material after excision of spots 1 and
2 for the rerunning experiment presented in
D, higher levels of radioactivity were used
in the experiment conducted with PGE1/
IBMX-treated cells. (D) Peptides 1 and 2
from the PGE1-treated cells were excised
from the gel and run again either alone (left
panels) or mixed with peptides 1 and 2 from
the experiment in Fig. 3 B (right panels;
equal counts of each).502 PKA Activation of Csk Abolishes TCR Signaling
Csk-S364C, was observed in vitro (Fig. 6 A). Coexpression
of wild-type Csk with PKA Cb showed a 1.8-fold increase
in Csk activity compared with Jurkat TAg T cells trans-
fected with the Csk construct together with a vector with
Cb in the reverse orientation (Fig. 6 B). However, in con-
trast to the 1.8-fold increase in activity of wild-type Csk by
treatment of Jurkat T cells with cAMP, the activity of the
mutant Csk-S364C enzyme was not affected by cAMP
(Fig. 6 C).
A PKA-Csk-Lck Inhibitory Pathway Mediates cAMP Regu-
lation of IL-2 Production.  To assess the downstream effects
of PKA-mediated activation of Csk on T cell activation, we
examined TCR-induced IL-2 production in Jurkat T cells
(clone E6.1). To avoid dilution by untransfected cells, we
developed a protocol for the selection of transfected cells.
Cotransfection with DNA encoding the rat NK cell recep-
tor NKR-P1A and magnetic bead selection for receptor al-
lowed purification of cells expressing green fluorescent pro-
tein (Fig. 7 A) or Csk (Fig. 7 B). TCR-induced IL-2
production was very sensitive to the levels of expressed
Csk, and a 3.5-fold overexpression reduced IL-2 secretion
almost down to basal levels (Fig. 7 C). Thus, although the
relative effect of cAMP was constant, the magnitude of the
inhibition by cAMP was strongly reduced at higher levels
of Csk expression (Fig. 7 C, s). The effect of mutagenesis
of S364 in Csk on the cAMP-inhibitable IL-2 production
was therefore analyzed at a 1.9:1 ratio of transfected over
endogenous Csk (arrow in Fig. 7 C) where changes in the
inhibition by cAMP could be measured readily. Expression
of Csk-S364C which has no PKA-phosphorylation site, re-
duced the cAMP inhibition of IL-2 production compared
with control or cells expressing wild-type Csk (Fig. 7 D; 30
vs. 50–60% inhibition). The presence of endogenous Csk
(1:1.9 versus mutant) explains why the inhibitory effect of
cAMP was not totally abrogated. Higher levels of Csk-
S364C expression by itself totally inhibited TCR-induced
IL-2 production, and the effect of cAMP could not be ana-
lyzed. In contrast, Lck overexpression (twofold) by itself
did not inhibit IL-2 production, which was fully sensitive
to cAMP inhibition. However, Lck-Y505F strongly re-
duced the inhibitory effects of cAMP on TCR-induced
IL-2 production (Fig. 7 E).
The PKA Type I-Csk-Lck Inhibitory Pathway Is Assembled
in Lipid Rafts. We have reported previously the localiza-
tion of PKA type I with the capped and activated TCR–
CD3 complex (17). More recently, the understanding has
been developed that proximal signaling events downstream
of the TCR occur in specialized cholesterol- and gly-
colipid-enriched membrane microdomains or lipid rafts
where signaling molecules such as Lck and LAT are tar-
geted (27, 31). The novel lipid raft–associated Cpb/PAG is
shown to interact with Csk in rat brain and in T cells via
phosphotyrosine 317 in human PAG (Y314 in rat Cbp;
references 9, 10). To analyze the subcellular distribution of
components of the novel PKA-Csk-Lck inhibitory path-
way mapped here, we purified lipid rafts by sucrose gradi-
ent centrifugation and fractionation of Triton X-100 lysates
of peripheral blood T cells. Pervanadate treatment of T
cells induced a strong tyrosine phosphorylation of the con-
stitutively lipid raft–associated LAT, and increased the
phosphotyrosine content of Cbp/PAG and Lck (Fig. 8 A)
as well as other proteins not associated with lipid rafts (Fig.
8 A, lanes 9–12). However, both Cbp/PAG and Lck were
phosphorylated also in resting peripheral T cells (Fig. 8 A,
top). Furthermore, analysis of the same fractions showed
that Csk, PKA RIa, and PKA C subunit are present in
lipid rafts of both activated (Fig. 8 B) and resting (data not
shown) T cells. In contrast, PKA RIIa is not detected in
rafts, consistent with our earlier observations showing that
PKA type I (RIa2C2), and not PKA type II (RIIa2C2), me-
diates the inhibitory effect of cAMP on T cell immune
function (16–18). Targeting of PKA type I may be medi-
ated by an A-kinase anchoring protein (AKAP; for a re-
view, see reference 32) directed to the RIa subunit and/or
by docking of the C subunit e.g., via a caveolin-like pro-
tein (33). The constitutive association of Csk with rafts is
consistent with the level of tyrosine phosphorylation of
Cbp/PAG in resting T cells.
To functionally analyze the effect of PKA on Csk in
rafts, we looked at Lck-defective JCaM1 T cells transfected
Figure 6. PKA phosphorylation of Csk-S364 is nec-
essary for the regulatory effect of cAMP on Csk. (A) In
vitro Csk kinase activities of Csk-wt, Csk-S364C, and
Csk-S339A/S340A/T341A (Csk-AAA) were exam-
ined in the presence of active or heat-inactivated PKA
Ca. (B) Csk kinase activity in anti-HA immunoprecip-
itates from Jurkat TAg T cells cotransfected with HA-
Csk-wt and PKA Cb subunit inserted in pEFneo in
sense or reverse orientation. Kinase activities were nor-
malized for levels of immunoreactive HA-Csk (means 6
SEM). Expression of Cb was also verified by immuno-
blotting. The data are representative of three indepen-
dent experiments. (C) Csk activity was assessed in anti-HA
immunoprecipitates of Jurkat TAg T cells transfected
with HA-Csk-wt or mutant HA-Csk-S364C (means 6
SEM). Cells were incubated in the presence or absence
of 8-CPT-cAMP (300 mM for 40 min), and immuno-
precipitations and kinase assays were performed as in B.
Western blot analysis confirmed equal levels of Csk ex-
pression.503 Vang et al.
with kinase-dead Lck (Lck-K273M) that cannot be auto-
phosphorylated at Y394 and therefore can only be tyrosine
phosphorylated at Y505 (by Csk). Both transfected Lck and
endogenous Csk were present in lipid rafts of these cells.
Furthermore, when transfected cells were incubated in the
presence of forskolin (to stimulate cAMP production), the
tyrosine phosphorylation of Lck-K273M isolated from rafts
increased 2.3-fold, indicating that Csk activity in rafts was
stimulated upon triggering of the cAMP-PKA pathway
(Fig. 9). Similar observations were made in whole cell ly-
sates (data not shown).
Discussion
Csk is present in all human cells as a key regulator of Src
kinases (7). The fact that the presence of Y505 in Lck is
essential for the inhibitory effect of cAMP on z chain phos-
phorylation and IL-2 production indicates that the PKA-
mediated phosphorylation of Csk may be a major mechanism
by which cAMP inhibits TCR-mediated T cell activation
(Fig. 10). A two- to fourfold increase in Csk activity by
phosphorylation of S364 appears to have similarly distinct
effects on T cell function as a two- to threefold Csk overex-
pression, which abolishes activation through the TCR (6)
Figure 7. Pertubation of a PKA-Csk-Lck regula-
tory pathway mediates the inhibitory effect of
cAMP on IL-2 secretion after T cell activation. (A)
To establish a method for selecting only cells trans-
fected with the gene of interest, Jurkat T cells were
cotransfected with plasmids directing expression of
a rat NK marker, NKR-P1A, and green fluorescent
protein (GFP; left panel; 60% transfection effi-
ciency, 47% double-positive cells), followed by
separation of NKR-P1A positive (right) from nega-
tive (middle) cells using anti–NKR-P1 mAb and
beads that allow detachment of cells after purifica-
tion. Purity of the positive population was rou-
tinely 90–97%. (B) Anti-HA blot of cells trans-
fected with HA-tagged Csk expression vectors and
purified by bead selection for the cotransfected
NKR-P1A. Negatively (2; lanes 1 and 3) and pos-
itively selected (1; lanes 2 and 4) cells are shown.
(C) Jurkat T cells (clone E6.1) were transfected
with Csk-wt expression vector at increasing doses
of DNA, and the following day cells (6 3 105, 0.3 3
106/ml) positively selected for cotransfectant were
stimulated by OKT3 (5 mg/ml) and PMA (10 nM)
in the absence (d) or presence (s) of 8-CPT-
cAMP (500 mM, 15 min pretreatment). After 20 h
of culture, supernatants were harvested and ana-
lyzed for secreted IL-2. Pelleted cells were sub-
jected to anti-Csk immunoblotting and densito-
metric scanning of levels of immunoreactive native
and transfected (running with somewhat lower mo-
bility) Csk. IL-2 levels were plotted relative to the
ratio of transfected over native Csk. Arrow indi-
cates the level of Csk expression used for the exper-
iment in D. Representative of two experiments.
(D) Positively selected Jurkat T cells expressing
HA-Csk-wt or mutant HA-Csk-S364C at twofold
above endogenous levels of Csk were stimulated
and analyzed together with vector-transfected cells
as in C for IL-2 secretion in the absence and pres-
ence of 8-CPT-cAMP. Percent inhibition of IL-2
secretion by cAMP for each cell culture is shown.
In cells transfected with HA-Csk-wt, the total IL-2
production is inhibited both in the presence and
absence of cAMP, whereas the ratio remains con-
stant. Inset shows equal levels of transfected Csk-wt
and Csk-S364C by anti-HA immunoblotting. Spe-
cific activities of wild-type and mutant Csk-S364C
were comparable (data not shown). Representative
of three experiments. (E) Jurkat T cells (five to six
individual cell cultures) were transfected with
empty vector (Control) or vectors directing expres-
sion of wild-type Lck and mutant Lck-Y505F that
cannot be phosphorylated by Csk, stimulated as in
C, and analyzed for IL-2 secretion (levels relative to
stimulated are shown).504 PKA Activation of Csk Abolishes TCR Signaling
and downstream IL-2 production (Fig. 7 C). Furthermore,
the stoichiometry of Csk phosphorylation by PKA in vitro
is 0.3–0.5 mol/mol of Csk under optimal conditions, indi-
cating a single site not fully phosphorylated (quite common
with bacterially produced protein). In vivo, we anticipate
that a specific pool of Csk may be preferentially phosphory-
lated by colocalized PKA and reaches a higher stoichiometry
and extent of activation. In addition, Jurkat and other leuke-
mic T cell lines have higher levels of tyrosine phosphoryla-
tion (34) and Src kinase activities (35) than peripheral T
cells. Thus, normal T cells appear to have a more controlled
and managed Lck activity that may implicate Csk regulation
and a PKA-Csk inhibitory pathway to a larger extent than
apparent from, for example transfection studies on Jurkat T
cells. Indeed, low level labeling of peptide 1 (representing
Csk-S364) was seen in the tryptic peptide mapping of Csk
from metabolically labeled unstimulated cells (Fig. 5 C)
which increased strongly by treatment with PGE1 alone
(data not shown). This indicates that this site is phosphory-
lated under physiological conditions. The mechanism for
Csk activation by S364 phosphorylation is currently under
investigation in our laboratory, and data in progress indicate
that interaction with the intrachain SH3 domain is impli-
cated in the PKA-mediated activation of Csk.
We have recently reported that the T cell dysfunction in
HIV can be reversed by inhibition of the increased activity
Figure 8. PKA and Csk are targeted to lipid rafts. Peripheral blood T
cells were left untreated (2PV) or treated with pervanadate for 5 min
(1PV) before homogenization in ice-cold lysis buffer with 1% Triton X-100
and separation in a 40–5% sucrose gradient. Fractions collected from the
top (1–12) were analyzed by immunoblotting for (A) phosphotyrosine
content and (B) distribution of Csk, PKA R and C subunits, and LAT.
Mobility of molecular weight markers as well as of Cbp/PAG, Lck, and
LAT are indicated in A. Blots in B represent parallel gel runs of the frac-
tions in A (1PV). Observations are representative of three or more ex-
periments.
Figure 9. Forskolin stimulation of cells increases the phosphorylation
of Y505 in Lck in lipid rafts. (A) Lck-deficient JCaM1 cells were trans-
fected with a plasmid encoding catalytically inactive Lck-K273M. After
harvesting, cells were homogenized in lysis buffer containing 0.7% Triton
X-100 and subsequently separated in a 40–5% sucrose gradient. Fractions
collected from the top (1–12) were analyzed by anti-Lck immunoblot-
ting. Fractions 2–4 represent lipid raft fractions. Both transfected Lck-
K273M and truncated catalytically inactive endogenous Lck are indicated.
(B) Lipid raft fractions (fractions 2–4) from A were mixed and solubilized
by addition of octyl-glucoside (50 mM). Thereafter, immunoprecipita-
tion (IP) with either normal rabbit serum (NRS) or anti-Csk Abs was
performed, and subsequent SDS-PAGE and anti-Csk immunoblotting
were conducted. Triton X-100 lysate of JCaM1 cells is shown as control.
(C) JCaM1 cells transfected with a plasmid encoding catalytically inactive
Lck-K273M (same cells as in A) were incubated in the absence (2) or
presence (1) of forskolin (100 mM) at 378C for 10 min; thereafter lipid
raft purification was performed as in A. Lipid raft fractions (2–4) were
mixed and solubilized by the addition of octyl-glucoside (50 mM), and
subjected to anti-Lck immunoprecipitation. After SDS-PAGE, the phos-
photyrosine content of Lck was assessed by immunoblotting with an-
tiphosphotyrosine Abs (4G10). Anti-Lck immunoblot (bottom) is shown
as control. Densitometric analysis of both blots was conducted to assess
the level of tyrosine phosphorylation of Lck-K273M.505 Vang et al.
of PKA type I (18), indicating that immunomodulation
through cAMP/PKA contributes to the pathogenesis of this
immunodeficiency. Inhibition of Lck through activation of
Csk provides a molecular mechanism for this effect. Fur-
thermore, PKA-mediated regulation of the activity of vari-
ous Src kinase family members by phosphorylation of Csk
may also provide a molecular mechanism for cAMP-medi-
ated regulation of both B and NK cell activation (36, 37).
Finally, Csk and Src kinases are expressed in other tissues,
including neuronal tissues (38), and the impact of cAMP
regulation of Csk in these tissues will be interesting to pur-
sue. The PKA phosphorylation site in Csk is conserved be-
tween vertebrates, suggesting that this site may have been
subject to selection pressure, but is only partially conserved
(RFS or KFT) in Csk homologous kinase (Chk/Lsk/Hyl/
Matk) and Csk-type protein kinase (Ctk/Bhk/Ntk).
In conclusion, we report the mapping of a PKA phos-
phorylation site on Csk and regulation of Csk activity by
cAMP/PKA. Localization of both Csk and PKA type I to
lipid rafts supports the notion that this novel inhibitory
pathway is assembled in membrane microdomains where it
can intersect TCR-induced signaling at a proximal level.
The presence of adenylyl cyclase that generates cAMP in
lipid rafts of S49 lymphoma cells further supports assembly
of the cAMP-PKA type I-Csk inhibitory pathway in lipid
rafts (Fig. 10; reference 39). The constitutive localization of
components of this pathway in lipid rafts may indicate that
a tonic level of inhibition of T cell activation is imposed on
resting T cells. PKA-mediated activation of Csk provides a
molecular mechanism for cAMP-dependent inhibition of
lymphocyte activation, and Csk-S364 and/or Lck-Y505
may be future targets for immunomodulating therapies.2
Furthermore, this mechanism may regulate signaling
through Src kinases in general.
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